Bruker Corporation announced the acquisition of biocrates life sciences ag on June 3, 2025. Biocrates, based in Innsbruck, Austria, is a global leader in mass spectrometry (MS)-based quantitative metabolite and lipid analysis kits, assays, software, and services.
The biocrates kits cover over 1,000 metabolites from more than 40 metabolite classes, and its technology platform combines innovative sample preparation, metabolite identification, and data analysis. This acquisition enhances Bruker’s MS-based metabolomics solutions.
The acquisition supports Bruker’s expansion into multiomics solutions, including instruments, reagents, software, and research services. This builds on prior acquisitions of proteomics kits, software, and services companies PreOmics and Biognosys, further integrating Bruker's multiomics approach.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.